​​Star of Excellence
Screen-less ECG Monitor (sl Monitor)
A novel, miniature, screen-less ElectroCardioGraph (ECG) monitor (“sl monitor”), developed completely in Qatar, by a joint effort of Cardio-thoracic surgery of Heart Hospital and the electrical engineering department of Qatar University. The device is a small rectangular box, which pairs up, by wireless means, to any smart mobile phone. The ECG can then be displayed on the phone’s screen.
​​Rising Star
Clinical Outcomes of Implementing Evidence-based Practice
Comprehensive venous thromboembolism (VTE) prevention for hospitalized patients is a quality and patient safety priority for healthcare organizations worldwide. Therefore, the HMC leadership identified VTE Prevention as an improvement and patient safety initiative for 2013-2014 under the Best Care Always Campaign. An organization wide program was implemented.
​​Awards of Merit
Delineating Exclusive Breastfeeding Barriers
This research sought to answer two questions: (1) Does the prevalence of breastfeeding in Qatar match the international prevalence? (2) What are the barriers to exclusive breastfeeding reported by women residing in the State of Qatar? The results showed that though the breastfeeding initiation rate was 94 %. By the time these infants were 6 months old, only 24% of them were still breastfeeding exclusively.  The most common reasons bottle-feeding was chosen included perception of lack of sufficient breast milk after delivery, lack of adequate knowledge about breastfeeding and mother’s return to work and easy accessibility and availability to formula.
​​Prevalence and Determinants of Depression
Depression is a widespread and serious mental health issue. A World Health Organization (WHO) 2012 report stated that the adolescent age group is at the highest risk for developing depression.

A cross sectional study was conducted of Qatari adolescents aged 14 to 19 years attending secondary school. The prevalence of depression was measured using an Arabic version of the Beck’s Depression Inventory-II (BDIII). The response rate was over 95 percent.